Elzbieta Zyner
Medical University of Łódź
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Elzbieta Zyner.
Dalton Transactions | 2010
Justyn Ochocki; Maria Kasprzak; Lilianna Chęcińska; Andrea Erxleben; Elzbieta Zyner; Leszek Szmigiero; Ariadna Garza-Ortiz; Jan Reedijk
Synthesis, structure and properties of two new flavanone complexes of Ru(ii) are described. The new complexes form during the reaction of ruthenium(iii) chloride with 3-aminoflavone (3-af) dissolved in an aliphatic alcohol. The formed products depend on the alcohol used and were found to be: cis-dichloridobis(3-imino-2-methoxyflavanone)ruthenium(ii)·3H(2)O (1) from a methanolic solution and cis-dichloridobis(3-imino-2-ethoxyflavanone)ruthenium(ii)·2H(2)O (2) from an ethanolic solution, in which the original ligand 3-af had been converted by dehydrogenative alcoholysis to an entirely new ligand. This paper presents the X-ray structure and detailed (1)H-NMR analysis of both new compounds, as well as the study of their antiproliferative activity. The coordination of Ru(ii) is octahedral with [RuCl(2)N(2)O(2)] chromophores, having trans chlorides and common Ru-L distances. Both 1 and 2 are highly cytotoxic towards the cisplatin resistant EJ and L1210 cell lines, and both complexes are as active as cisplatin in the sensitive cell lines. They display the ability to overcome cisplatin resistance in the drug resistant sub-lines EJcisR and L1210R. The present evidence suggests that the mechanism of biological activity may be different for these ruthenium compounds compared to cisplatin.
Investigational New Drugs | 2005
Beata Kosmider; Izabela Wojcik; Regina Osiecka; Jacek Bartkowiak; Elzbieta Zyner; Justyn Ochocki; Pawel P. Liberski
Lung cancer remains one of the most common causes of cancer-related death worldwide. Approximately 80% is histologically non-small cell lung carcinoma (NSCLC) and in about 70% of patients it is an unresectable type. Clinical studies indicated that application of platinum derivatives caused good results and combinations of platinum with other agents could improve median survivals. In view of the central problem of sufficient efficiency of drugs in chemotherapy, efforts have focused on the development of alternative platinum-based analogues that can be more effective in cancer treatment. cis-bis(3-aminoflavone)dichloroplatinum(II) (cis-Pt(II) complex of 3-aminoflavone) represents a novel class of platinum-based potential antitumour agents. In order to evaluate the degree of apoptosis, acridine orange/ethidium bromide and Hoechst 33258/propidum iodide double staining as well as RT-PCR (P53 and BAX expression evaluation) were used in lung cancer cell line A549 after treatment with this compound in comparison with cis-diamminedichloroplatinum(II) (cis-DDP). Apoptotic cells at early and late stages and also necrotic ones were observed after usage of cis-Pt(II) complex of 3-aminoflavone and the percentage of these cells outnumbered the values obtained after cis-DDP application. The former compound induced a higher percentage of P53 and BAX expression in A549 cells in comparison with the latter one. Results indicate the beneficial properties of cis-Pt(II) complex of 3-aminoflavone as a potential antitumor drug.
Journal of Inorganic Biochemistry | 2011
Maria Kasprzak; Leszek Szmigiero; Elzbieta Zyner; Justyn Ochocki
In this study we examined their proapoptotic activity of cis-dichloridobis(3-imino-2-methoxyflavanone)ruthenium(II)3H(2)O (1) and cis-dichloridobis(3-imino-2-ethoxyflavanone)ruthenium(II)2H(2)O (2) towards human bladder carcinoma cell line EJ and its cisplatin resistant subline EJcisR. On the basis of the experiments we carried out, it may be concluded, that: CDDP (cis-diamminedichloridoplatinum) resistance of EJcisR cells is probably based on partial loss of apoptotic pathway activating caspase-8 and increased resistance to DNA strand breaks and/or alkali-labile sites. Increased glutathione levels, as well as activity of P-gp transporter seems to be not relevant in this case. The proapoptotic activity of the ruthenium compounds is higher than that of cisplatin. Higher proapoptotic activity of 1 and 2 when compared to CDDP may be due to the presence of large, lipophilic flavanone-based ligands that may facilitate their trans-membrane transport and their redox activity. 1 and 2 induce apoptosis apparently in more than one way. Although caspase-8 activation and DNA strand breaks and/or alkali-labile sites are caused by the compounds, their ability to cause the oxidative stress in the cells may also participate in apoptosis induction.
Drug Research | 2011
Beata Kosmider; Sunny A. Anuels; Dolf Evenberg; Elzbieta Zyner; Karim Bahmed; Regina Osiecka; Justyn Ochocki
cis-DDP (cis-diamminedichloroplatinum(II), CAS 15663-27-1) is widely used in chemotherapy of many types of cancer. However, besides effectiveness, it gives many side effects which limit its clinical application. Therefore, nowadays studies are focused on searching for novel analogs of cis-DDP, at least equally effective in chemotherapy but less toxic. One of them might be cis-BAFDP (cis-bis(3-aminoflavone)dichloroplatinum(II)) with one of the hydrogen atoms of the amino group of cis-DDP replaced by a flavone ring. 3-Aminoflavone (AF) which posseses the desired NH2 group has been used as non-leaving ligand. The complex has been obtained in the reaction of AF and K2PtCl4. There are no data concerning evaluation of structural studies of cis-BAFDP, the beneficial anticancer properties of which were proved in vitro and in vivo. Therefore it was worthwhile to undertake a confirmation of the chemical structure of this compound by applying various spectroscopic techniques especially because of its potential pharmacological application. With this aim in mind this compound was characterized by: IR, 1H NMR, 195Pt NMR, UV absorption and fluorescence spectroscopy. Moreover, stronger apoptosis induction by cis-BAFDP than cis-DDP in the human nonsmall cancer cell line A549 was observed using Hoechst 33258/propidium iodide double staining.
Mutation Research-genetic Toxicology and Environmental Mutagenesis | 2004
Beata Kosmider; Regina Osiecka; Ewa Ciesielska; Leszek Szmigiero; Elzbieta Zyner; Justyn Ochocki
Journal of Pharmaceutical and Biomedical Analysis | 2005
Arzum Erdem; Beata Kosmider; Regina Osiecka; Elzbieta Zyner; Justyn Ochocki; Mehmet Ozsoz
Mutation Research-genetic Toxicology and Environmental Mutagenesis | 2004
Beata Kosmider; Kalina Wyszyńska; Ewa Janik-Spiechowicz; Regina Osiecka; Elzbieta Zyner; Justyn Ochocki; Ewa Ciesielska; Wojciech Wasowicz
Canadian Journal of Physiology and Pharmacology | 2004
Beata Kosmider; Elzbieta Zyner; Regina Osiecka; Justyn Ochocki
Inorganica Chimica Acta | 2009
Bogumiła Żurowska; Andrea Erxleben; Łukasz Glinka; Małgorzata Łęczycka; Elzbieta Zyner; Justyn Ochocki
Mutation Research-genetic Toxicology and Environmental Mutagenesis | 2006
Beata Kosmider; Izabela Zawlik; Pawel P. Liberski; Regina Osiecka; Elzbieta Zyner; Justyn Ochocki; Jacek Bartkowiak